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Abstract
Background: Lymphadenectomy is debated in early stages endometrial cancer. Moreover, a new FIGO
classification of endometrial cancer, merging stages IA and IB has been recently published. Therefore, the aims of
the present study was to evaluate the relevance of the sentinel node (SN) procedure in women with endometrial
cancer and to discuss whether the use of the 2009 FIGO classification could modify the indications for SN
procedure.
Methods: Eighty-five patients with endometrial cancer underwent the SN procedure followed by pelvic
lymphadenectomy. SNs were detected with a dual or single labelling method in 74 and 11 cases, respectively. All
SNs were analysed by both H&E staining and immunohistochemistry. Presumed stage before surgery was assessed
for all patients based on MR imaging features using the 1988 FIGO classification and the 2009 FIGO classification.
Results: An SN was detected in 88.2% of cases (75/85 women). Among the fourteen patients with lymph node
metastases one-half were detected by serial sectioning and immunohistochemical analysis. There were no false
negative case. Using the 1988 FIGO classification and the 2009 FIGO classification, the correlation between
preoperative MRI staging and final histology was moderate with Kappa = 0.24 and Kappa = 0.45, respectively.
None of the patients with grade 1 endometrioid carcinoma on biopsy and IA 2009 FIGO stage on MR imaging
exhibited positive SN. In patients with grade 2-3 endometrioid carcinoma and stage IA on MR imaging, the rate of
positive SN reached 16.6% with an incidence of micrometastases of 50%.
Conclusions: The present study suggests that sentinel node biopsy is an adequate technique to evaluate lymph
node status. The use of the 2009 FIGO classification increases the accuracy of MR imaging to stage patients with
early stages of endometrial cancer and contributes to clarify the indication of SN biopsy according to tumour
grade and histological type.
Background
Introduction of a new cancer classification is required
when sufficient evidence-based data proved their impact
on the staging itself. Recently, the scientific community
with the support of the Federation International of
Gynecology and Obstetrics (FIGO) as well as other
international scientific societies and agencies has consid-
ered that revision of the classification of endometrial
cancer was necessary. This was mainly based on data
showing that the prognosis of stage IA grade 1-2, and
IB grade 1-2, had similar 5-year survival. Based on the
favourable prognosis for the former stage IA and IB
patients, the FIGO Committee elected to merge these
stages so that now stage IA involves the endometrium
and/or less than one-half myometrial invasion and IB is
equal to or greater than the outer one-half of the myo-
metrium [1-3].
The impact of a new classification implies that studies
using the former classification become obsolete rending
necessary temporally to express data using the two clas-
sifications to adapt therapeutic strategy. This is particu-
larly important concerning the requirement of
lymphadenectomy that is associated with morbidity in
women with endometrial cancer that are often obese
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with hypertension and diabetes. Since 1988, FIGO classi-
fication ruled on surgical staging of endometrial cancer,
based on peritoneal cytology, hysterectomy, bilateral
salpingo-oophorectomy and pelvic/paraaortic lymphade-
nectomy [4]. Previous studies attempted to identify
patients that could benefit of lymphadenectomy accord-
ing to presumed FIGO stage assessed by imaging techni-
ques, histological type and histological grade obtained
on biopsy [5]. Recent randomized trials have suggested
that lymphadenectomy has little relevance on survival
and can be omitted in early stages of endometrial cancer
[6]. These results were based on routine histology with
hematoxylin and eosin staining (H&E) without the use
of neither sentinel node procedure nor serial sectioning
and immunohistochemical staining. Hence, it is likely
that some patients are under staged linked to misdiag-
nosis of micrometastases [7-9]. Although there is no
consensus on sentinel node biopsy neither on the prog-
nostic relevance of micrometastases in endometrial can-
cer, Yasbushita et al demonstrated the relation between
the presence of micrometastases and the risk of recur-
rence [10]. Therefore, the aims of the present study
were to evaluate the relevance of the sentinel node (SN)
procedure in women with endometrial cancer and to
discuss whether the use of the 2009 FIGO classification
could modify the indications for SN procedure.
Methods
Patients
Between July 2002 and March 2009, 85 women with
suspected endometrial cancer were referred to the gyne-
cology unit of Tenon Hospital, Paris, France. Among
the 85 women, results of the first 46 women have been
previously published [7]. All the women underwent
endometrial biopsy under hysteroscopy guidance to
diagnose cancer and preoperative MR imaging to assess
the disease stage. All the women underwent peritoneal
cytology, the SN procedure with pelvic lymphadenect-
omy, bilateral salpingo-oophorectomy and hysterectomy
by laparoscopy. Women with presumed involvement of
cervical stroma on MR imaging had radical hysterect-
omy instead of simple hysterectomy.
Medical records were reviewed to determine age, body
mass index (BMI), tumour stage, histology, surgical pro-
cedure, intra- and postoperative complications, and
length of hospital stay. Outcome was obtained from the
outpatient records. The study was approved by the insti-
tutional review board (CEROG-2010-34) and all patients
provided written informed consent.
Sentinel Node Procedure Technique
The sentinel node procedure technique was performed
as previously described [7]. In summary, four intracervi-
cal injections of 0.2 mL of unfiltered technetium were
administered the day before surgery. Scintigraphic
images were obtained 2 h after the injections and then
every 30 min to detect the sentinel node (SN).
Before starting surgery, under general anaesthesia,
patent blue was injected intracervically at 3 and 9 h
clock. The pelvic and lower para-aortic regions were
inspected carefully for lymph ducts and dye uptake by
lymph nodes. Radioactive pelvic and para-aortic lymph
nodes were located by using an endoscopic gamma
probe (Eurorad, Strasbourg, France) inserted through
the 12-mm suprapubic trocar.
Radioactive lymph nodes were sought before opening
the peritoneum. After locating the SN, the peritoneum
was opened and each blue and/or radioactive lymph
node was removed separately in endoscopic bags. Pelvic
lymphadenectomy was systematically performed after
the SN procedure. All lymphatic tissue was removed
and extracted in an endoscopic bag. Women with clear-
cell or serous endometrial cancer had systematic omen-
tectomy with para-aortic lymphadenectomy. Usual
boundaries of para-aortic lymphadenectomy were
respected with the left renal vein as the upper limit. The
absence of residual pelvic or para-aortic radioactivity
was verified after lymphadenectomy.
Histology
SN and non-SN were analyzed by a pathologist. Lymph
nodes with macroscopic metastases were sectioned.
Normal-appearing SNs were cut perpendicular to the
long axis. All SN were submitted to intraoperative
imprint cytology. Air-dried cytological smears were pre-
pared by scraping the cut surfaces and staining with a
rapid May-Grünwald-Giemsa method. Each half-SN was
sectioned at 3-mm intervals. Each 3-mm section was
analyzed at four additional levels of 150 μm and four
parallel sections; one was used for H&E staining, and
H&E-negative sections were examined by immunohisto-
chemistry (IHC) with an anticytokeratin antibody cock-
tail (cytokeratins AE1-AE3; Dako Corporation, Glostrup,
Denmark). Non-SN were submitted totally and blocked
individually after 3-mm sectioning and H&E staining.
The size of lymph node metastases was estimated with
an eyepiece micrometer. A micrometastasis was defined
as a single focus of metastatic disease per lymph node,
measuring no more than 2 mm. The presence of single
noncohesive tumour cells was recorded as submicrome-
tastasis [7,11,12] SNs were considered positive when
they contained macrometastase, micrometastase, or
submicrometastase.
Analysis of SN
SNs were recorded as blue-stained and/or radioactive (if
the in vivo count exceeded three times the background).
The false-negative rate was defined as the number of
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procedures with a negative SN and one or more positive
non-SN, divided by the number of procedures with any
positive pelvic or para-aortic node.
Adjuvant Therapy after Surgery
The 1988 FIGO classification was used in the decision
making process for adjuvant therapy after surgery [4].
Adjuvant therapy was not recommended for women
with stage IA disease, regardless of the grade. Women
with stage IB, IC, IIA or IIB disease had brachytherapy.
Women with stage III disease or higher had external
pelvic radiotherapy.
Brachytherapy consisted of 20 Gy given 5-6 weeks
after surgery. External pelvic radiation therapy consisted
of 40 Gy, divided into 2.25 Gy per fraction, four days a
week. All fields were treated daily with 15 megavoltage
units. When concurrent chemoradiotherapy was indi-
cated, chemotherapy was given during the first and
fourth weeks of radiation therapy and consisted of a
continuous 5-fluorouracil infusion (750 mg/m2/day),
and a cisplatin bolus (20-25 mg/m2/day) 1 h before
radiotherapy, on days 1, 2, 4 and 5. Patients with posi-
tive aortic nodes received extended-field radiation up to
the level of T12-L1.
FIGO staging
Using the 1988 FIGO classification, presumed stage
before surgery was assessed for all patients based on
MR imaging features. Then, after surgery and definitive
histology, the final FIGO stage was determined. For
each patient, the same analysis was performed using the
2009 FIGO classification.
Statistical Analysis
Statistical analysis was based on Student’s t-test and the
Mann-Whitney test for parametric and nonparametric
continuous variables, respectively, and the chi-square
test or Fisher’s exact test, as appropriate, for categorical
variables. The Mc Nemar test for paired samples was
used to compare the detection methods. Values of p <
0.05 were considered to denote significant differences.
Results
Epidemiological and preoperative characteristics of the
population (Table 1)
Median age was 66 years (range: 43-87 years). Eighty-
one patients (95%) were menopausal, of whom twenty-
one (24.7%) had hormonal replacement therapy. The
median body mass index (BMI) was 26.5 kg/m2 (range:
17.8-45.3 kg/m2). Nineteen patients (22.3%) were obese
(BMI > 30 kg/m2). Ten patients had a history of breast
cancer but none of them underwent a tamoxifen treat-
ment. None of the patients had a history of hereditary
non-polyposis colorectal cancer (HNPCC) syndrome.
All patients had uterine bleeding investigated by hys-
teroscopy and biopsy. Endometrial biopsy showed endo-
metrioid adenocarcinoma, serous papillary carcinoma,
clear-cell adenocarcinoma, carcinosarcoma and adenos-
quamous carcinoma in 73 cases, 5 cases, 4 cases, and
one case each, respectively. The tumor grade on biopsy
was 1, 2, 3 and undetermined in 41 cases, 22 cases,
11 cases and 11 cases, respectively.
SN Procedure
The SN procedure was performed by laparoscopy and
laparotomy in 79 and 6 cases, respectively. A laparo-
tomic SN procedure was used initially in four patients
with a history of pelvic surgery, and conversion to lapar-
otomy was required in two cases because of severe obe-
sity. Seventy-five patients (88.2%) had pelvic
lymphadenectomy and ten patients (11.8%) had both
pelvic and paraaortic lymphadenectomy for clear cells
adenocarcinoma and serous adenocarcinoma in 5 cases
each. The SN procedure involved dual and single label-
ing in 74 and 11 cases, respectively. None of the women
had radioactive labeling alone. An SN was detected in
88.2% of cases (75/85 women). The SN detection rates
with dual and single labeling were 91.9% and 63.6%
(p = 0.01), respectively. A mean (± standard deviation,
SD) of 2.6 ± 1.2 and 1.8 ± 0.5 SN per patient were
detected with the dual and single labels, respectively
(p = 0.2).
The total number of removed pelvic nodes was 1105
(median: 13, range: 2-26) including SN. The total number
of right and left external iliac nodes, excluding SNs, were
470 (median: 5, range: 1-13) and 435 (median: 5, range:
1-13), respectively. The median number of para-aortic
Table 1 Epidemiological and histological characteristics
of the 85 patients with endometrial cancer
Characteristics Patients
n = 85
Age 66 (range 43-87)
Hypertension 34 (39%)
Hormone replacement therapy 21 (24%)
Obesity (BMI ≥ 30) 19 (22.3%)
Histology:
Endometrioid adenocarcinoma 73 (86%)
Adenosquamous adenocarcinoma 1 (1%)
Serous papillary adenocarcinoma 5 (6%)
Clear cell adenocarcinoma 5 (6%)
Carcinosarcoma 1 (1%)
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nodes was 15 (range: 5-26). Among the 75 patients with
at least one identified SN, the mean number of SN per
patient was 2.68 (range: 1-7). A total of 201 SN were
removed. The SNs were blue and radioactive, radioactive
alone and blue alone in 105, 96 and 10 cases, respectively.
SNs were detected bilaterally in 49 (57.6%) of the 85
patients. The SNs were located in the region of the exter-
nal iliac (lateral group), the iliac vessel bifurcation, the
common iliac and the aortic bifurcation in 160 (78%), 33
(16%), 7 cases (6%) and 1 case (1%), respectively. No SNs
were detected in the parametrium or para-aortic area.
The patient with an SN at the aortic bifurcation had two
SNs in the external iliac region. None of the patients had
an isolated paraaortic SN.
Histology of sentinel and non sentinel nodes (Table 2)
Fourteen (18.6%) of the 75 patients in whom at least one
SN was detected had a positive SN, with macrometastasis
in three cases and micrometastasis in eleven cases. The
median number of SN per patient was 3 (range: 1-7). The
median number of non-SN removed per patient was 10.5
(range: 2-26). Intraoperative imprint cytology confirmed
two of three macrometastasis. SN micrometastasis and
macrometastasis was diagnosed postoperatively by H&E
staining in seven women. All SNs that were negative by
H&E staining were examined by immunohistochemistry
(IHC), and seven additional patients were found to be
positive. A total of 895 pelvic non-SNs were removed.
Thirteen of the fourteen patients with positive SNs had
no positive non-SN, while a patient with positive SNs (a
macrometastasis and isolated tumour cells) had two
positive non-SNs. None of the patients with no positive
SNs had a positive non-SNm i.e. there were no false-
negative case. None of the ten patients in whom no SN
was detected had a positive non-SN.
Correlation between MR imaging staging and definitive
histology (Table 3)
Using 1988 FIGO classification, MR imaging detected an
endometrial cancer of stage IA, IB, IC, IIA, IIB or IIIA dis-
ease in 14 cases (17.3%), 35 cases (43.2%), 27 cases (33.3%),
3 cases (3.7%), 2 cases (2.5%) and 1 case (1.1%), respec-
tively. Three patients were not staged on MR imaging.
When considering myometrial invasion using 1988
FIGO classification, among the fourteen women with
presumed stage IA disease on MR imaging, final histol-
ogy showed FIGO stage IA, IB, IC and IIB disease in
28.5%, 43%, 14.2% and 14.2%, respectively. Among the
35 women with presumed stage IB disease on MR ima-
ging, final histology showed FIGO stage IA, IB, IC and
IIA disease in 31.5%, 40%, 23% and 5.5%, respectively.
Among the 27 women with presumed stage IC disease
on MR imaging, final histology showed FIGO stage IB,
IC, IIA and IIIA disease in 18.5%, 74%, 3.7% and 3.7%,
respectively. Among the three women with presumed
stage IIA disease on MR imaging, final histology showed
FIGO stage IB and IC disease in 67% and 33%, respec-
tively. Among the two women with presumed stage IIB
disease on MR imaging, final histology showed FIGO
stage IB, IIB disease in 50% each. The only woman with
presumed stage IIIA on MR imaging had a stage IC on
final histology. Therefore, 38 of the 82 women (47.5%)
were correctly staged by MRI. The correlation between
preoperative MRI staging using 1988 FIGO classification
and final histology was moderate (Kappa = 0.24)
Impact of new FIGO classification (table 4)
Using 2009 FIGO classification, MR imaging detected an
endometrial cancer of stage IA, IB, II, or IIIA disease in
Table 2 Tumour characteristics and MRI staging in
















1 IC IB adenosquamous 1 Negative Positive
2 IC IB Endometrioid 3 Negative Positive
3 IC IB Endometrioid 2 Positive
4 IC IB Serous papillary 1 Positive
5 IC IB Endometrioid 3 Negative Positive
6 IC IB Endometrioid 2 Positive
7 IIA IA Endometrioid 2 Positive
8 IB IA Clear cells 2 Positive
9 IC IB Endometrioid 2 Positive
10 IC IB Endometrioid 1 Negative Positive
11 IC IB Serous papillary 1 Positive
12 IC IB Clear cells 3 Positive
13 IB IA Endometrioid 2 Negative Positive
14 IIIA IIIA Clear cells 3 Positive
MRI: Magnetic Resonance Imaging; IHC: immunohistochemistry
Table 3 Relation between presumed MR imaging stage of
endometrial cancer and final stage after definitive
histology according to 1988 FIGO classification
FIGO stage after definitive histology
Presumed
Stage on MRI
IA IB IC IIA IIB IIIA Total
IA 28.5% 43% 14.2% 0 14.2% 0 14
IB 31.5% 40% 23% 5.5% 0 0 35
IC 0 18.5% 74% 3.7% 0 3.7 27
IIA 0 67% 33% 0 0 0 3
IIB 0 50% 0 0 0 50% 2
IIIA 0 0 100% 0 0 0 1
Total 18.3% 34% 39% 3.5% 2.5% 2.5% 82
Kappa test = 0.24 (moderate)
Ballester et al. BMC Cancer 2010, 10:465
http://www.biomedcentral.com/1471-2407/10/465
Page 4 of 8
52 cases (63.5%), 27 cases (32.9%), 2 cases (2.4%), and
1 case (1.2%), respectively.
When considering myometrial invasion using 2009
FIGO classification, among the 52 women with pre-
sumed stage IA disease on MR imaging, final histology
showed stage IA, IB, II, IIIA disease in 73%, 19.2%, 7.8%
and none, respectively. Among the 27 women with pre-
sumed stage IB on MR imaging, final histology showed
FIGO stage IA, IB, II and IIIA disease in 18.5%, 74%,
3.7% and 3.7%, respectively. Among the two women
with pre-operative stage II, final histology showed FIGO
stage IA and II in 50% respectively. The only woman
with a preoperative stage IIIA had a FIGO stage IB at
final histology. Therefore, 59 of the 82 women (70%)
were correctly staged by MRI. The correlation between
MR imaging staging and final histology was moderate
(Kappa= 0.45).
None of the 27 patients with no or less than half myo-
metrial infiltration and grade 1 tumor exhibited positive
SN. Three of the 18 patients (16.6%) with no or less
than half myometrial infiltration and grade 2-3 tumor
had positive SN. Four of the 12 patients (33.3%) with
more than half myometrial infiltration and grade 1
tumor had positive SN. Six of 12 patients (50%) with
more than half myometrial infiltration and grade 2-3
tumor had positive SN. One of the seven patient (14.3%)
with invasion of cervical stroma or serosa of the corpus
uteri had a positive SN.
Discussion
The present study suggests that sentinel node biopsy is
an adequate technique to evaluate lymph node status.
The use of the 2009 FIGO classification increases the
accuracy of MR imaging to stage patients with early
stages of endometrial cancer and contributes to clarify
the indication of SN biopsy according to tumour grade
and histological type.
To our knowledge, the present study is the largest ser-
ies on SN in endometrial cancer reporting a high SN
detection reaching 88.2%. Among the fourteen patients
with lymph node metastases one-half were detected by
serial sectioning and immunohistochemical analysis.
These results are in accordance with those of a recent
review of literature on SN in endometrial cancer show-
ing that SN detection rate was depending on sites of
injection, technique of labeling, and histological techni-
que for SN analysis [8]. A debate exists on the best site
for injections of patent blue and radiocolloid [9,13-18].
Like in the present study, cervical injection has the
advantage to be easy and reproducible but exposes to
the risk to ignore direct para-aortic drainage. Conver-
sely, injection under hysteroscopic guidance is a more
invasive technique and raises the issue whether SN
biopsy must reflect tumor or organ lymphatic drainage.
Another option could be the use of both dual cervical
and colorimetric subserosal injection at the first step of
surgery [19]. So far, no trial comparing various injection
sites is available to standardize the SN biopsy in patients
with endometrial cancer. As in the present study, a
higher SN detection rate was noted for technique using
dual labeling ranging from 70% to 100% compared to
colorimetric or radiocolloid technique alone [8]. Finally,
the contribution of serial sectioning and IHC has been
proved to detect micrometastases although issues exist
on their prognostic relevance [8-10,20-22]. Moreover,
previous studies on SN in cervical cancer have under-
lined the risk of confounding micrometastases with
staining of benign inclusions or mesothelial cells [23].
Despite these limitations on the SN biopsy in endome-
trial cancer, the absence of false-negative rate observed
in our experience and in previous studies suggests its
relevance in routine practice. This is also supported by
the histological validation of the SN biopsy published by
Delpech et al [16].
The results of the present study are partly in disagree-
ment with those of two randomized trials showing no ben-
efit for pelvic lymphadenectomy on overall or recurrence-
free survival in patients with early endometrial cancer.
The ASTEC study showed a hazard ratio (HR) of 1.16
(95% CI 0.87-1.54; p = 0.31) in favor of hysterectomy and
bilateral salpingo-oophorectomy without lymphadenect-
omy and an absolute difference in 5-year overall survival
of 1% (95% CI -4 to 6) [6]. With adjustment for baseline
characteristics and pathology details, the HR for overall
survival was 1.04 (0.74-1.45; p = 0.83) and for recurrence-
free survival was 1.25 (0.93-1.66; p = 0.14). However, med-
ian follow-up was of only 37 months not allowing proving
the positive impact to remove micrometastases. Indeed, a
previous study showed that micrometastasis removal in
women with endometrial cancer was associated with a
significant increase in disease-free survival and that the
rate of recurrence reached 35.7% in patients with micro-
metastases over 40 months of follow-up [10]. In a second
Table 4 Relation between MR imaging stage and FIGO
stage at final histology according to the new
classification
FIGO stage after definitive histology
Presumed
Stage on MRI
IA IB II IIIA Total
IA 73% 19.2% 7.8% 0 52
IB 18.5% 74% 3.7% 3.7% 27
II 50% 0 50% 0 2
IIIA 0 100% 0 0 1
Total 53.5% 37.8% 7.3% 1.4% 82
Kappa test = 0.45 (moderate)
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randomized trial, Benedetti et al found that both early and
late postoperative complications occurred statistically
significantly more frequently in patients undergoing pelvic
systematic lymphadenectomy but was associated with
improved surgical staging with detection of lymph node
metastases in 13.3% that is concordant with our rate of
metastases in patients with grade 2-3 endometrioid carci-
noma and stage IA on MR imaging [24]. However, in
these two trials, SN biopsy, serial sectioning and IHC were
not performed exposing to underestimate the rate of
lymph node metastases and to under-treatment [16].
It is clear that the use of the 2009 FIGO classification
with fewer stages may impact on surgical strategy parti-
cularly concerning the need for lymphadenectomy. In
our experience, none of the patients with grade 1 endo-
metrioid carcinoma and invasion of less than half of the
myometrium exhibited positive SN suggesting that lym-
phadenectomy as well as SN procedure could be
omitted. Eltabbakh et al underlined the risk of underes-
timation for grade 1 endometrioid carcinoma on biopsy
with an upstaging on definitive histology in one-third of
cases [25]. Hence the combination of histological type
and grading on biopsy and presumed MR imaging sta-
ging reduce the risk of lymph node misdiagnosis. Our
results are in accordance with a recent report using the
same protocol for SN biopsy in 42 patients with grade 1
endometrioid carcinoma showing that only 11% of
patients with stage I had positive SN [26]. Moreover, as
in our experience, the risk of positive non-SN in case of
positive SN was 0% for patients with stage I endome-
trioid carcinoma. This is particularly true when a sys-
tematic IHC on SNs is used. Indeed, Altgassen et al
demonstrated that when SNs were IHC stained, the sen-
sitivity of SN biopsy rose to 83.3% with a NPV of 93.8%
[27]. Although recent trials underlined the low relevance
of systematic lymphadenectomy in patients with grade
2-3 endometrioid carcinoma and invasion of less than
half of the myometrium, our relative high incidence of
positive SN justify its use. Indeed, for these patients, our
rate of positive SN reached 16.6% with an incidence of
micrometastases of 50% addressing the issue on the eva-
luation of lymph node status. Moreover, all positive SNs
were found in patients with grade 2 endometrioid carci-
noma suggesting that a cut-off exists between grade 1
and grade 2-3 endometrioid carcinoma. These results
are supported by a recent review of Bernardini & Mur-
phy addressing issue on both the use of the SN techni-
que and the consideration of a binary grading system to
simplify triaging of patients [28]. For patients with inva-
sion equal to or more than half of the myometrium
whatever the tumor grade, the rate of positive SN was
31.6%. Moreover, the rate of positive SN was 14.3% for
grade 1 and invasion equal to or more than half of the
myometrium underlining that evaluation of lymph node
status cannot be omitted. For patients with non-endo-
metrioid carcinoma, the sample size was too low to
draw conclusions but for stage IA non endometrioid
carcinoma whatever tumor grade, the rate of positive
SN was 10% and reached 44.4% for stage IB. These
results are in accordance with those of Mariani et al
recommending systematic pelvic and para-aortic
lymphadenectomy in non-endometrioid carcinoma [29].
The main issue for women with endometrial cancer is
to assess the presumed FIGO stage to determine surgi-
cal management. In addition to preoperative endome-
trial biopsy, MR imaging is the main admitted imaging
technique to stage endometrial cancer. In our experi-
ence, using the 1988 FIGO classification, only one-third
of patients were adequately staged. Misdiagnosis
occurred mainly for patients with 1988 stage IA carci-
noma hence the use of the 2009 FIGO classification
merging stage IA and IB contributes to increase the
accuracy of MR imaging. Despite these modifications,
the accuracy of MR imaging to determine myometrial
invasion remained relatively moderate. Hence, these
results reinforced the potential relevance of SN biopsy.
Previous meta-analysis on MRI have demonstrated a
high overall performance of MRI reaching 0.87 (95% CI:
0.85-0.89) with a performance for myometrial and cervi-
cal invasion of 0.83 (95% CI: 0.79-0.87) and 0.92 (95%
CI: 0.87-0.95), respectively [30]. The discrepancies
between our results and those of the meta-analysis are
probably linked to the inclusion in our study of patients
with early stages of disease while the meta-analysis
included mainly patients with 1988 stage IB, IC and IIIa.
Some limits of the present study have to be under-
lined. First, although the present study is the largest ser-
ies, our incidence of patients with lymph node
metastasis was too low to build a nomogramme to iden-
tify patients that could benefit of the SN biopsy. How-
ever, the low accuracy of imaging techniques such as
MR imaging and PET-FDG reinforces the potential rele-
vance of SN especially in case of endometrial cancer
affecting elderly women often obese and with co-mor-
bidities. Second, in accordance with French guidelines,
except for clear cells and serous papillary carcinomas,
no systematic para-aortic lymphadenectomy was per-
formed. This could represent a potential cause of false
negative rate underestimation. Third, the absence of
consensus on SN technique rends comparison difficult
between series. We opted for a dual cervical injection
thank to its easiness and reproducibility although some
para-aortic involvement could be missed by ignoring
direct para-aortic drainage impacting on both SN detec-
tion and false negative rate. However, previous studies
have emphasized on the low incidence of isolated para-
aortic metastases [31]. Abu-Rustum et al in a large ser-
ies of endometrial cancer reported that only 1.6% had
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positive paraaortic nodes with negative pelvic nodes.
Moreover, among the 187 patients with a final diagnosis
of grade 1 endometrial cancer, only 2 (1%) had a posi-
tive paraaortic node with negative pelvic nodes [32].
Fourth, in the present study, the comparison of the two
FIGO classifications mainly based on myometrial invol-
vement could be a potential bias by ignoring the impact
of lymph node status. Moreover, the role of MRI to
assess FIGO classification of women with endometrial
cancer remains a matter of debate. However, in a review
of the literature, Selman et al underline that among the
various imaging techniques available to determine endo-
metrial cancer stage, MRI appears the best option.
Finally, we did not used a systematic CAM immunos-
taining to differentiate true micrometastases from
mesothelial staining that could overestimate the rate of
lymph node metastases [33].
In conclusion, our results suggest the relevance of SN
biopsy to determine lymph node status in patients with
endometrial cancer. The combination of tumor grade,
histological type and features of MR imaging associated
to the use of the 2009 FIGO classification of endome-
trial cancer contribute to clarify the good candidates for
SN biopsy.
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